# RARB

Source: https://onco.cc/targets/rarb/  
OnCo record `rarb` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.

## Summary

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, animal model 0.65, genetic association 0.00, clinical 0.97).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: retinoic acid receptor beta; Retinoic acid receptor beta; NR1B2; RRB2; RARbeta; RAR-beta
- Tags: cancer-genes-wave
- Symbol: RARB
- Class: transcription
- Biology: Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Location: Nucleus; Cytoplasm (UniProt). Locus 3p24.2 (HGNC).
- Where found: Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059); Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076); Acute myeloid leukaemia: Open Targets association 0.60 with acute myeloid leukaemia (MONDO_0018874); Acute promyelocytic leukaemia: Open Targets association 0.59 with acute promyelocytic leukaemia (MONDO_0012883)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9865: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9865
- UniProt P10826: https://www.uniprot.org/uniprotkb/P10826/entry
- NCBI Gene 5915: https://www.ncbi.nlm.nih.gov/gene/5915
- Ensembl ENSG00000077092: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077092

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)

---
JSON: https://onco.cc/api/v1/entities/rarb.json